Wall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to Hold

Key Points

• TransMedics Group has been downgraded from a "buy" to a "hold" rating by analysts at Wall Street Zen, indicating a shift in market sentiment towards the stock.
• Despite the downgrade, analysts such as Piper Sandler and Oppenheimer have set target prices that reflect a potential upside, with Oppenheimer increasing its price target from $130.00 to $150.00.
• TransMedics reported strong financial performance with a 37.7% year-over-year revenue increase in its latest quarterly earnings, exceeding analyst expectations in both earnings per share and revenue.

Wall Street Zen lowered shares of TransMedics Group (NASDAQ:TMDX - Free Report) from a buy rating to a hold rating in a report released on Saturday morning.

A number of other brokerages also recently weighed in on TMDX. Piper Sandler reissued an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Canaccord Genuity Group boosted their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. Oppenheimer raised their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Monday, August 25th. Finally, Morgan Stanley boosted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $122.11.

TransMedics Group Trading Down 2.7%

TMDX traded down $2.89 during midday trading on Friday, reaching $104.05. 1,370,684 shares of the company were exchanged, compared to its average volume of 852,488. The stock has a market capitalization of $3.55 billion, a P/E ratio of 53.91 and a beta of 2.18. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The stock's 50-day simple moving average is $118.62 and its 200 day simple moving average is $103.89. TransMedics Group has a one year low of $55.00 and a one year high of $169.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business's revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, analysts forecast that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of TMDX. Amalgamated Bank boosted its position in shares of TransMedics Group by 0.8% during the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company's stock worth $1,285,000 after purchasing an additional 80 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of TransMedics Group by 2.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock worth $482,000 after acquiring an additional 100 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company's stock worth $72,000 after acquiring an additional 108 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in TransMedics Group by 4.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company's stock worth $455,000 after buying an additional 142 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of TransMedics Group by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,842 shares of the company's stock worth $1,989,000 after purchasing an additional 148 shares during the period. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.